Authors :
Shivani Agarwal; Kartikay Prakash; Rahul Chauhan; Akash Sharma
Volume/Issue :
Volume 9 - 2024, Issue 12 - December
Google Scholar :
https://tinyurl.com/msadshmy
Scribd :
https://tinyurl.com/3vfx4jfr
DOI :
https://doi.org/10.5281/zenodo.14576746
Abstract :
Vitiligo is a complex skin disorder
characterized by the loss of melanocytes, leading to
patchy depigmentation of the skin. Although the exact
etiology remains uncertain, factors such as genetics,
autoimmune responses, and oxidative stress have been
implicated in its development. The Indian system of
medicine and modern pharmacological treatments have
been explored for managing vitiligo. This review paper
provides a comprehensive overview of the
pharmacological treatment of vitiligo, emphasizing three
major classes of treatment: topical, systemic, and
depigmentation therapies. Topical treatments include
corticosteroids, calcineurin inhibitors, vitamin D3
analogues, pseudocatalase, 5-fluorouracil, methotrexate,
PF2A, basic fibroblast growth factor (bFGF), and Janus
kinase (JAK) inhibitors. These treatments target
immune responses and promote melanocyte function to
restore skin pigmentation. Systemic treatments involve
corticosteroids, apremilast, JAK inhibitors, minocycline,
statins, methotrexate, azathioprine, cyclosporine, and
mycophenolate mofetil, aiming to suppress immune
activity and stabilize the progression of vitiligo.
Therapies for depigmentation aim to lighten the
remaining pigmented areas, providing a more uniform
skin tone. By examining the effectiveness and safety of
these treatment options, this paper aims to guide
clinicians in selecting the most appropriate
pharmacological interventions for vitiligo patients.
Additionally, insights into the Indian system of medicine
offer potential alternatives for treatment.
Keywords :
Vitiligo Treatment, Topical Therapy, Systemic Therapy, Depigmentation Therapy, Indian System of Medicine and Autoimmune Response.
References :
- Gauthier Y, Cario Andre M, Taïeb A: A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy?. Pigment Cell Res. 2003, 16:322-32. 10.1034/j.1600-0749.2003.00070.x
- Krüger C, Schallreuter KU: A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012, 51:1206-12. 10.1111/j.1365-4632.2011.05377.x
- van den Boorn JG, Konijnenberg D, Dellemijn TA, et al.: Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol. 2009, 129:2220-32. 10.1038/jid.2009.32
- Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE: Current and emerging treatments for vitiligo. J Am Acad Dermatol. 2017, 77:17-29. 10.1016/j.jaad.2016.11.010
- Dina Y, McKesey J, Pandya AG: Disorders of hypopigmentation. J Drugs Dermatol. 2019, 18:s115-6.
- Slominski AT, Kim TK, Hobrath JV, et al.: Endogenously produced nonclassical vitamin D hydroxy metabolites act as "biased" agonists on VDR and inverse agonists on RORα and RORγ. J Steroid Biochem Mol Biol. 2017, 173:42-56. 10.1016/j.jsbmb.2016.09.024
- Kwinter J, Pelletier J, Khambalia A, Pope E : High-potency steroid use in children with vitiligo: a retrospective study. J Am Acad Dermatol. 2007, 56:236-41. 10.1016/j.jaad.2006.08.017
- Costin GE, Hearing VJ: Human skin pigmentation: melanocytes modulate skin color in response to stress . FASEB J. 2007, 21:976-94. 10.1096/fj.06-6649rev
- Khojah HM, Alharbi AG, Alshaeri AA, Alahmadi YM, Elbadawy HM: Impact of narrow-band ultraviolet B radiation therapy on the quality of life of patients with vitiligo. J Taibah Univ Med Sci. 2021, 16:843-8. 10.1016/j.jtumed.2021.04.012
- Silverberg NB. The epidemiology of vitiligo. Curr Derm Rep 2015;4:36-43.
- Sehgal VN, Srivastava G. Vitiligo: Compendium of clinico-epidemiological features. Indian J Dermatol VenereolLeprol2007;73:149-56.
- Liu JB, Li M, Yang S, Gui JP, Wang HY, Du WH, et al. Clinical profiles of vitiligo in China: An analysis of 3742 patients. Clin Exp Dermatol 2005;30:327-31.
- Fatani MI, AlSharif SH, Alfif KA, Khan AS, Hussain WA, Banjar AA. The clinical patterns of vitiligo “hospital-based study” in Makkah region, Saudi Arabia. J. Dermatol Dermatolsurg2014;18:17-21.
- van Geel N, Speeckaert R, Taieb A, Picardo M, Böhm M, Gawkrodger DJ, et al. Koebner’s phenomenon in vitiligo: European position paper. Pigment Cell Melanoma Res 2011;24:564-73
- Millington GW, Levell NJ. Vitiligo: The historical curse of depigmentation. Int J Dermatol 2007;46:990-5.
- Taieb A, Alomar A, Böhm M, Dell'anna ML, De Pase A, Eleftheriadou V, Ezzedine K, Gauthier Y, Gawkrodger DJ, Jouary T, et al: Guidelines for the management of vitiligo: The European dermatology forum consensus. Br J Dermatol 168: 5‑19, 2013.
- Gawkrodger DJ, Ormerod AD, Shaw L, Mauri‑Sole I, Whitton ME, Watts MJ, Anstey AV, Ingham J, Young K, Therapy Guidelines and Audit Subcommittee, British Association of Dermatologists, et al: Guideline for the diagnosis and management of vitiligo. Br J Dermatol 159: 1051‑1076, 2008.
- Njoo MD, Spuls PI, Bos JD, Westerhof W and Bossuyt PM: Nonsurgical repigmentation therapies in vitiligo. Meta‑analysis of the literature. Arch Dermatol 134: 1532‑1540, 1998.
- Faria AR, Tarlé RG, Dellatorre G, Mira MT and Castro CC: Vitiligo‑Part 2‑classification, histopathology and treatment. An Bras Dermatol 89: 784‑790, 2014.
- Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE and Group VW: Current and emerging treatments for vitiligo. J Am Acad Dermatol 77: 17‑29, 2017.
- Bleuel R and Eberlein B: Therapeutic management of vitiligo. J Dtsch Dermatol Ges 16: 1309‑1313, 2018.
- Whitton ME, Pinart M, Batchelor J, Leonardi‑Bee J, González U, Jiyad Z, Eleftheriadou V and Ezzedine K: Interventions for vitiligo. Cochrane Database Syst Rev: CD003263, 2015 doi: 10.1002/14651858.CD003263.pub5.
- Lotti T, Agarwal K, Podder I, Satolli F, Kassir M, Schwartz RA, Wollina U, Grabbe S, Navarini AA, Mueller SM and Goldust M: Safety of the current drug treatments for vitiligo. Expert Opin Drug Saf 19: 499‑511, 2020.
- Kwinter J, Pelletier J, Khambalia A and Pope E: High‑potency steroid use in children with vitiligo: A retrospective study. J Am Acad Dermatol 56: 236‑241, 2007.
- Ballona R: ‘Soft steroids’ o corticoidessuavesenDermatologíaPediátrica. Dermatol Pediatr Lat 3: 150‑157, 2005.
- Felsten LM, Alikhan A and Petronic‑Rosic V: Vitiligo: A comprehensive overview Part II: Treatment options and approach to treatment. J Am Acad Dermatol 65: 493‑514, 2011.
- Lee JH, Kwon HS, Jung HM, Lee H, Kim GM, Yim HW and Bae JM: Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: A systematic review and Meta‑analysis. JAMA Dermatol 155: 929‑938, 2019.
- Chang HC, Hsu YP and Huang YC: The effectiveness of topical calcineurin inhibitors compared with topical corticosteroids in the treatment of vitiligo: A systematic review and meta‑analysis. J Am Acad Dermatol 82: 243‑245, 2020.
- Ebrahim HM, Elkot R and Albalate W: Combined microneedling with tacrolimus vs. tacrolimus monotherapy for vitiligo treat ment. J Dermatolog Treat: Feb 11, 2020 (Epub ahead of print).
- Abd‑Elazim NE, Yassa HA and Mahran AM: Microdermabrasion and topical tacrolimus: A novel combination therapy of vitiligo. J Cosmet Dermatol 19: 1447‑1455, 2020.
- Bikle D and Christakos S: New aspects of vitamin D metabolism and action‑addressing the skin as source and target. Nat Rev Endocrinol 16: 234‑252, 2020.
- Holick MF: Vitamin D deficiency. N Engl J Med 357: 266‑281, 2007.
- Aranow C: Vitamin D and the immune system. J Investig Med 59: 881‑886, 2011.
- Chiavérini C, Passeron T and Ortonne JP: Treatment of vitiligo by topical calcipotriol. J EurAcad Dermatol Venereol 16: 137‑138, 2002.
- Rodríguez‑Martín M, García Bustínduy M, Sáez Rodríguez M and Noda Cabrera A: Randomized, double‑blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo. Br J Dermatol 160: 409‑414, 2009.
- Kumaran MS, Kaur I and Kumar B: Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treat ment of localized vitiligo. J EurAcad Dermatol Venereol 20: 269‑273, 2006.
- Ibrahim ZA, Hassan GF, Elgendy HY and Al‑Shenawy HA: Evaluation of the efficacy of transdermal drug delivery of calcipotriol plus betamethasone versus tacrolimus in the treatment of vitiligo. J Cosmet Dermatol 18: 581‑588, 2019.
- Naini FF, Shooshtari AV, Ebrahimi B and Molaei R: The effect of pseudocatalase/superoxide dismutase in the treatment of vitiligo: A pilot study. J Res Pharm Pract 1: 77‑80, 2012.
- Schallreuter KU, Krüger C, Würfel BA, Panske A and Wood JM: From basic research to the bedside: Efficacy of topical treatment with pseudocatalase PC‑KUS in 71 children with vitiligo. Int J Dermatol 47: 743‑753, 2008.a
- Bakis‑Petsoglou S, Le Guay JL and Wittal R: A randomized, double‑blinded, placebo‑controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo. Br J Dermatol 161: 910‑917, 2009.
- Alshiyab DM, Al‑Qarqaz FA, Muhaidat JM, Alkhader YS, Al‑Sheyab RF and Jafaar SI: Comparison of the efficacy of Tacrolimus 0.1% ointment and Tacrolimus 0.1% plus topical pseudocatalase/superoxide dismutase gel in children with limited vitiligo: A randomized controlled trial. J Dermatolog Treat: Feb 11, 2020 (Epub ahead of print).
- Agarwal K, Podder I, Kassir M, Vojvodic A, Schwartz RA, Wollina U, Valle Y, Lotti T, Rokni GR, Grabbe S and Goldust M: Therapeutic options in vitiligo with special emphasis on immunomodulators: A comprehensive update with review of literature. Dermatol Ther 33: e13215, 2020.
- Tsuji T and Hamada T: Topically administered fluorouracil in vitiligo. Arch Dermatol 119: 722‑727, 1983.
- Abdelwahab M, Salah M, Samy N, Rabie A and Farrag A: Effect of Topical 5‑fluorouracil alone versus its combination with erbium:YAG (2940 nm) laser in treatment of vitiligo. Clin Cosmet Investig Dermatol 13: 77‑85, 2020.
- Sethi S, Mahajan BB, Gupta RR and Ohri A: Comparative evaluation of the therapeutic efficacy of dermabrasion, dermabrasion combined with topical 5% 5‑fluorouracil cream, and dermabrasion combined with topical placentrex gel in localized stable vitiligo. Int J Dermatol 46: 875‑879, 2007.
- Anbar T, Westerhof W, Abdel‑Rahman A, El‑Khayyat M and El‑Metwally Y: Treatment of periungual vitiligo with erbium‑YAG‑laser plus 5‑flurouracil: A left to right comparative study. J Cosmet Dermatol 5: 135‑139, 2006.
- Mohamed HA, Mohammed GF, Gomaa AH and Eyada MM: Carbon dioxide laser plus topical 5‑fluorouracil: A new combi nation therapeutic modality for acral vitiligo. J Cosmet Laser Ther 17: 216‑223, 2015.
- Mina M, Elgarhy L, Al‑Saeid H and Ibrahim Z: Comparison between the efficacy of microneedling combined with 5‑fluo rouracil vs. microneedling with tacrolimus in the treatment of vitiligo. J Cosmet Dermatol 17: 744‑751, 2018.
- Abdelmaksoud A, Dave DD, Lotti T and Vestita M: Topical methotrexate 1% gel for treatment of vitiligo: A case report and review of the literature. Dermatol Ther 32: e13013, 2019.
- Eldelee SA, Gheida SF, Sarhan NI, Ibrahim ZA and Elfar NN: Evaluation of the effect of combined intralesional injection of prostaglandin F2α with narrow band UVB phototherapy in treatment of resistant cases of vitiligo. J Dermatolog Treat: Sep 4, 2019 (Epub ahead of print).
- Jha AK, Prasad S and Sinha R: Bimatoprost ophthalmic solution in facial vitiligo. J Cosmet Dermatol 17: 437‑440, 2018.
- Kanokrungsee S, Pruettivorawongse D and Rajatanavin N: Clinical outcomes of topical bimatoprost for nonsegmental facial vitiligo: A preliminary study. J Cosmet Dermatol 20: 812‑818, 2021.
- Nowroozpoor Dailami K, Hosseini A, RahmatpourRokni G, Saeedi M, Morteza‑Semnani K, Sadeghi Z, Ghasemzadeh Diva SM, Goldust M, Lotti T, Vojvodic A, et al: Efficacy of topical latanoprost in the treatment of eyelid vitiligo: A randomized, double‑blind clinical trial study. Dermatol Ther 33: e13175, 2020.
- Kamala Subhashini P, Sankar K, Chandrakala K and Venkataramana V: Comparative study of efficacy and safety of topical active fragment of basic fibroblast growth factor (B FGF) 0.1% solution V/S betamethasone valerate 0.1% ointment in the treatment of vitiligo patients. IOSR J Dental Med Sci 14: 41‑47, 2015.
- Shah B, Godse K, Mahajan S, Grandhi S, Shendkar S, Sharma A, Teli C, Pathak R and Parsad D: Efficacy and safety of basic fibroblast growth factor (bFGF) related decapeptide solution plus Tacrolimus 0.1% ointment versus Tacrolimus 0.1% ointment in the treatment of stable vitiligo. Dermatol Ther 32: e13109, 2019.
- Liu LY, Strassner JP, Refat MA, Harris JE and King BA: Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol 77: 675‑682.e671, 2017.
- Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H and Lui H: Parametric modeling of narrowband UV‑B phototherapy for vitiligo using a novel quantitative tool: The Vitiligo Area Scoring Index. Arch Dermatol 140: 677‑683, 2004.
- Rothstein B, Joshipura D, Saraiya A, Abdat R, Ashkar H, Turkowski Y, Sheth V, Huang V, Au SC, Kachuk C, et al: Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol 76: 1054‑1060.e1, 2017.
- Rosmarin D, Pandya AG, Lebwohl M, Grimes P, Hamzavi I, Gottlieb AB, Butler K, Kuo F, Sun K, Ji T, et al: Ruxolitinib cream for treatment of vitiligo: A randomised, controlled, phase 2 trial. Lancet 396: 110‑120, 2020.
- Mobasher P, Guerra R, Li SJ, Frangos J, Ganesan AK and Huang V: Open‑label pilot study of tofacitinib 2% for the treatment of refractory vitiligo. Br J Dermatol 182: 1047‑1049, 2020.
- Kim SM, Lee HS and Hann SK: The efficacy of low‑dose oral corticosteroids in the treatment of vitiligo patients. Int J Dermatol 38: 546‑550, 1999.
- Seiter S, Ugurel S, Tilgen W and Reinhold U: Use of high‑dose methylprednisolone pulse therapy in patients with progressive and stable vitiligo. Int J Dermatol 39: 624‑627, 2000.
- Imamura S and Tagami H: Treatment of vitiligo with oral corticosteroids. Dermatology 153: 179‑185, 1976.
- Banerjee K, Barbhuiya JN, Ghosh AP, Dey SK and Karmakar PR: The efficacy of low‑dose oral corticosteroids in the treatment of vitiligo patient. Indian J Dermatol VenereolLeprol 69: 135‑137, 2003.
- Pasricha JS and Khaitan BK: Oral mini‑pulse therapy with beta methasone in vitiligo patients having extensive or fast‑spreading disease. Int J Dermatol 32: 753‑757, 1993.
- Kanwar AJ, Mahajan R and Parsad D: Low‑dose oral mini‑pulse dexamethasone therapy in progressive unstable vitiligo. J Cutan Med Surg 17: 259‑268, 2013.
- Radakovic‑Fijan S, Fürnsinn‑Friedl AM, Hönigsmann H and Tanew A: Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol 44: 814‑817, 2001.
- Majid I, Imran S and Batool S: Apremilast is effective in control ling the progression of adult vitiligo: A case series. Dermatol Ther 32: e12923, 2019.
- Huff SB and Gottwald LD: Repigmentation of tenacious vitiligo on apremilast. Case Rep Dermatol Med 2017: 2386234, 2017.
- Craiglow BG and King BA: Tofacitinib citrate for the treatment of vitiligo: A pathogenesis‑directed therapy. JAMA Dermatol 151: 1110‑1112, 2015.
- Komnitski M, Komnitski A, Komnitski Junior A and Silva de Castro CC: Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation. An Bras Dermatol 95: 473‑476, 2020.
- Scheinberg M, Ferreira SB and Santos DDCB: Tofacitinib‑induced remission simultaneously in arthritis and vitiligo. Eur J Rheumatol 8: 55‑56, 2021.
- Song X, Xu A, Pan W, Wallin B, Kivlin R, Lu S, Cao C, Bi Z and Wan Y: Minocycline protects melanocytes against H2O2‑induced cell death via JNK and p38 MAPK pathways. Int J Mol Med 22: 9‑16, 2008.
- Parsad D and Kanwar A: Oral minocycline in the treatment of vitiligo‑a preliminary study. Dermatol Ther 23: 305‑307, 2010.
- Singh A, Kanwar AJ, Parsad D and Mahajan R: Randomized controlled study to evaluate the effectiveness of dexamethasone oral minipulse therapy versus oral minocycline in patients with active vitiligo vulgaris. Indian J Dermatol VenereolLeprol 80: 29‑35, 2014.
- Njoo MD, Das PK, Bos JD and Westerhof W: Association of the Kobner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol 135: 407‑413, 1999.
- Siadat AH, Zeinali N, Iraji F, Abtahi‑Naeini B, Nilforoushzadeh MA, Jamshidi K and Khosravani P: Narrow‑ band ultraviolet B versus oral minocycline in treatment of unstable vitiligo: A prospective comparative trial. Dermatol Res Pract 2014: 240856, 2014.
- Al‑Kuraishy H, Hussian N, Al‑Naimi M and Al‑Gareeb A: Statins role in vitiligo: A mini‑review. Turkish J Dermatol 14: 1‑7, 2020.
- Agarwal P, Rashighi M, Essien KI, Richmond JM, Randall L, Pazoki‑Toroudi H, Hunter CA and Harris JE: Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo. J Invest Dermatol 135: 1080‑1088, 2015.
- Nguyen S, Chuah SY, Fontas E, Khemis A, Jhingan A, Thng STG and Passeron T: Atorvastatin in combination with narrowband UV‑B in adult patients with active vitiligo: A randomized clinical trial. JAMA Dermatol 154: 725‑726, 2018.
- Iraji F, Banihashemi SH, Faghihi G, Shahmoradi Z, Tajmirriahi N and Jazi SB: A comparison of betamethasone valerate 0.1% cream twice daily plus oral simvastatin versus betamethasone valerate 0.1% Cream alone in the treatment of vitiligo patients. Adv Biomed Res 6: 34, 2017.
- Noël M, Gagné C, Bergeron J, Jobin J and Poirier P: Positive pleiotropic effects of HMG‑CoA reductase inhibitor on vitiligo. Lipids Health Dis 3: 7, 2004.
- Vanderweil SG, Amano S, Ko WC, Richmond JM, Kelley M, Senna MM, Pearson A, Chowdary S, Hartigan C, Barton B and Harris JE: A double‑blind, placebo‑controlled, phase‑II clinical trial to evaluate oral simvastatin as a treatment for vitiligo. J Am Acad Dermatol 76: 150‑151.e3, 2017.
- Alghamdi K and Khurrum H: Methotrexate for the treatment of generalized vitiligo. Saudi Pharm J 21: 423‑424, 2013.
- Garza‑Mayers AC and Kroshinsky D: Low‑dose methotrexate for vitiligo. J Drugs Dermatol 16: 705‑706, 2017.
- Nageswaramma S, Vani T and Indira N: Efficacy of methotrexate in vitiligo. IOSR J Dental Med Sci 17: 16‑19, 2018.
- Singh H, Kumaran MS, Bains A and Parsad D: A random ized comparative study of oral corticosteroid minipulse and low‑dose oral methotrexate in the treatment of unstable vitiligo. Dermatology 231: 286‑290, 2015.
- ElGhareeb MI, Metwalli M and AbdelMoneim N: Combination of oral methotrexate and oral mini‑pulse dexamethasone vs. either agent alone in vitiligo treatment with follow up by dermoscope. Dermatol Ther 33: e13586, 2020.
- Madarkar M, Ankad B and Manjula R: Comparative study of safety and efficacy of oral betamethasone pulse therapy and azathioprine in vitiligo. Clin Dermatol Rev 3: 121‑125, 2019.
- Radmanesh M and Saedi K: The efficacy of combined PUVA and low‑dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatolog Treat 17: 151‑153, 2006.
- Taneja A, Kumari A, Vyas K, Khare AK, Gupta LK and Mittal AK: Cyclosporine in treatment of progressive vitiligo: An open‑label, single‑arm interventional study. Indian J Dermatol VenereolLeprol 85: 528‑531, 2019.
- Mutalik S, Shah S, Sidwadkar V and Khoja M: Efficacy of cyclosporine after autologous noncultured melanocyte transplantation in localized stable vitiligo‑a pilot, open label, comparative study. Dermatol Surg 43: 1339‑1347, 2017.
- Bishnoi A, Vinay K, Kumaran MS and Parsad D: Oral mycophenolate mofetil as a stabilizing treatment for progressive non‑segmental vitiligo: Results from a prospective, randomized, investigator‑blinded pilot study. Arch Dermatol Res: Jul 31, 2020 (Epub ahead of print).
- Grimes PE and Nashawati R: Depigmentation therapies for vitiligo.Dermatol Clin35: 219‑227, 2017.
Vitiligo is a complex skin disorder
characterized by the loss of melanocytes, leading to
patchy depigmentation of the skin. Although the exact
etiology remains uncertain, factors such as genetics,
autoimmune responses, and oxidative stress have been
implicated in its development. The Indian system of
medicine and modern pharmacological treatments have
been explored for managing vitiligo. This review paper
provides a comprehensive overview of the
pharmacological treatment of vitiligo, emphasizing three
major classes of treatment: topical, systemic, and
depigmentation therapies. Topical treatments include
corticosteroids, calcineurin inhibitors, vitamin D3
analogues, pseudocatalase, 5-fluorouracil, methotrexate,
PF2A, basic fibroblast growth factor (bFGF), and Janus
kinase (JAK) inhibitors. These treatments target
immune responses and promote melanocyte function to
restore skin pigmentation. Systemic treatments involve
corticosteroids, apremilast, JAK inhibitors, minocycline,
statins, methotrexate, azathioprine, cyclosporine, and
mycophenolate mofetil, aiming to suppress immune
activity and stabilize the progression of vitiligo.
Therapies for depigmentation aim to lighten the
remaining pigmented areas, providing a more uniform
skin tone. By examining the effectiveness and safety of
these treatment options, this paper aims to guide
clinicians in selecting the most appropriate
pharmacological interventions for vitiligo patients.
Additionally, insights into the Indian system of medicine
offer potential alternatives for treatment.
Keywords :
Vitiligo Treatment, Topical Therapy, Systemic Therapy, Depigmentation Therapy, Indian System of Medicine and Autoimmune Response.